Drug Approval | July 05, 2022
Sanofi flu vaccines licensed and approved for 2022-2023 influenza season
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
The Ayushman Bharat Digital Mission (ABDM) aims to replicate this success in healthcare delivery by building an equitable, accessible and inclusive ecosystem
Increased and timely testing will enable early identification of COVID cases and help to curb spread of the infection among the community
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Subscribe To Our Newsletter & Stay Updated
